BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on
developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases.
In collaboration with the
Max Planck Institute for Multidisciplinary Sciences
Max Planck Institute for Multidisciplinary Sciences () is a research institute of the Max Planck Society, located in Göttingen, Germany. It was formed on January 1, 2022, through a merger of Max Planck Institute for Biophysical Chemistry and Max ...
(MPG) and the University Medical Center Göttingen (UMG), both in
Germany
Germany, officially the Federal Republic of Germany, is a country in Central Europe. It lies between the Baltic Sea and the North Sea to the north and the Alps to the south. Its sixteen States of Germany, constituent states have a total popu ...
, BiondVax develops nanosized antibody (NanoAb) therapies for diseases such as
COVID-19
Coronavirus disease 2019 (COVID-19) is a contagious disease caused by the coronavirus SARS-CoV-2. In January 2020, the disease spread worldwide, resulting in the COVID-19 pandemic.
The symptoms of COVID‑19 can vary but often include fever ...
,
asthma
Asthma is a common long-term inflammatory disease of the airways of the lungs. It is characterized by variable and recurring symptoms, reversible airflow obstruction, and easily triggered bronchospasms. Symptoms include episodes of wh ...
and
psoriasis
Psoriasis is a long-lasting, noncontagious autoimmune disease characterized by patches of abnormal skin. These areas are red, pink, or purple, dry, itchy, and scaly. Psoriasis varies in severity from small localized patches to complete b ...
.
History
Since its founding, BiondVax has executed eight
clinical trials
Clinical trials are prospective biomedical or behavioral research studies on human subject research, human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel v ...
, including a seven-country, 12,400-participant Phase 3 trial of a prior
influenza vaccine
Influenza vaccines, colloquially known as flu shots or the flu jab, are vaccines that protect against infection by influenza viruses. New versions of the vaccines are developed twice a year, as the influenza virus rapidly changes. While their ...
candidate, and owns and operates a biologics manufacturing facility for housing its laboratories, production facilities and offices.
In December 2021, BiondVax signed definitive agreements with the
Max Planck Society
The Max Planck Society for the Advancement of Science (; abbreviated MPG) is a formally independent non-governmental and non-profit association of German research institutes. Founded in 1911 as the Kaiser Wilhelm Society, it was renamed to the M ...
– parent organization of the Max Planck Institute for Multidisciplinary Sciences – and the UMG to enter into a strategic collaboration for the development and commercialization of
COVID-19
Coronavirus disease 2019 (COVID-19) is a contagious disease caused by the coronavirus SARS-CoV-2. In January 2020, the disease spread worldwide, resulting in the COVID-19 pandemic.
The symptoms of COVID‑19 can vary but often include fever ...
NanoAbs.
See also
*
Health care in Israel
Healthcare in Israel is Universal health care, universal and participation in a medical insurance plan is compulsory. All Israeli residents are entitled to basic health care as a fundamental right. The Israeli healthcare system is based on the N ...
*
Science and technology in Israel
Science and technology in Israel is one of the country's most developed sectors. Israel spent 4.3% of its gross domestic product (GDP) on civil research and development in 2015, the highest ratio in the world. In 2019, Israel was ranked the worl ...
References
{{reflist
Companies listed on the Nasdaq
Pharmaceutical companies
Pharmaceutical companies of Israel